Another robot deal for J&J shows up lack of Verb results
Johnson & Johnson is going in hard on robotics, but its first big move here has still not paid off.
Upcoming events – Biomarin’s achondroplasia hope and Apellis’s clash with Alexion
Biomarin awaits pivotal data on one of its growth drivers, while Apellis seeks to take off on Pegasus.
GTX Medical gains a new technology and loses a competitor
In buying a company previously thought of as a competitor GTX hopes to dominate the spinal cord injury space.
Alexion pays Achillion a $930m complement
A week after UCB bought Ra to get hold of its complement inhibitor, Alexion takes out Achillion for much the same reason.
Ipsen doubles down on rare bone disease
Today’s deal with Blueprint gives Ipsen two shots at Fop, but makes its takeout of Clementia look even more expensive.
Reata looks to outsmart Abbvie again
Fresh from buying omaveloxolone and bardoxolone rights back from Abbvie, Reata sees the first part of the puzzle fall into place.
UCB goes to Ra for a complementary approach
The $2bn takeout of Ra Pharmaceuticals provides solace for investors bemoaning the biotech market’s poor performance.
Upcoming events – Sage targets depression and Biogen aims for lupus
Sage's big depression readout looms, while Biogen hopes for a mid-stage hit in lupus.
The contrasting fortunes of Envista and Smiledirectclub
Two dental companies go public inside a week, with very different results.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.